Friday 19 December 2014

New Indications for Somatostatin Analogs

(MedPage Today) -- FDA okayed pasireotide for acromegaly and lanreotide for gastroenteropancreatic neuroendocrine tumors. via MedPageToday.com - medical news plus CME for physicians Read More Here..
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)